Sarepta Therapeutics Business Summary

Sarepta Therapeutics, Inc. (SRPT) operates a commercial-stage biopharmaceutical business model primarily driven by net product sales of its precision genetic medicine portfolio for Duchenne muscular dystrophy (DMD). Revenue is bifurcated into two primary segments: its established phosphorodiamidate morpholino oligomer (PMO) franchise—comprising EXONDYS 51, VYONDYS 53, and AMONDYS 45—and its pioneering gene therapy, ELEVIDYS. The company further supplements its top line through strategic collaboration and royalty agreements, most notably a global partnership with Roche that provides milestone payments and non-cash collaboration income. As of early 2026, Sarepta maintains a dominant market position as the first-mover in DMD gene therapy, though it faces intensifying competition from NS Pharma’s VILTEPSO, Pfizer’s fordadistrogene movaparvovec, and emerging next-generation candidates from Dyne Therapeutics and Solid Biosciences. Despite recent commercial headwinds and safety-related label updates for ELEVIDYS, the company is strategically positioned to achieve non-GAAP profitability and positive cash flow by mid-2026 through aggressive educational initiatives and international expansion. Originally founded in 1980 as AntiVirals, Inc. by Dwight Weller and Milton Zuker, Sarepta is currently led by CEO and President Douglas S. Ingram, a former Allergan executive who has steered the company through multiple FDA approvals but recently announced his retirement effective by the end of 2026. The technical and scientific trajectory is spearheaded by Dr. Louise Rodino-Klapac, President of R&D and Technical Operations, a renowned gene therapy pioneer whose work was foundational to the ELEVIDYS program. The executive suite is rounded out by CFO Ryan Wong and Chief Commercial Officer Patrick Moss, both of whom are focused on the company's 2026 financial reset. Sarepta’s strategic direction is heavily influenced by a concentrated institutional investor base, including BlackRock, Vanguard, and Capital International Investors, alongside a significant strategic equity stake held by Roche. The Board of Directors, chaired by Dr. M. Kathleen Behrens, provides oversight with a heavy emphasis on biopharma commercialization and R&D excellence.